CClinicalTrials.gg
CompletedNCT06100757Updated Oct 31, 2023

Effect of Leadless Pacing on Heart Function

An interventional study of Micra Transcatheter Pacing System (TPS° and Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR in Pacing-Induced Cardiomyopathy, sponsored by Universitaire Ziekenhuizen KU Leuven. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-31.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 5 months after the study started (first participant enrolled May 2018, registered Oct 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This prospective, un-blinded, randomized, noninferiority, single centre study with 12 month follow-up included patients who were scheduled for a single-chamber PM implant. Patients were 1:1 randomized to undergo the implantation of a conventional VVI pacing system (Medtronic, Advisa ADSR03) with a ventricular pacing lead (Medtronic, 5076-58) in the right ventricle (called 'conventional group') or to be implanted with a leadless Micra TPS (called 'Micra group').

The primary objective was to assess and compare the mechanical impact of right ventricular pacing using the Micra TPS versus a conventional PM on the left ventricular function.

Read the detailed description

The primary endpoint was to assess the mechanical impact of the Micra TPS on the left ventricular function. The investigators measured the change of Global Longitudinal Strain (GLS) over one year after pacemaker implantation.

As secondary endpoint, the investigators studied the effect of the Micra TPS on the right ventricle using speckle tracking for 2-D myocardial motion estimation. The investigators also assessed conventionally the function of the right ventricle using tricuspid annular plane systolic excursion (TAPSE) in accordance with the guidelines of the European Association of Cardiovascular Imaging and American Society of Echocardiography. Evolution of clinical and biological parameters as NYHA (New York Heart Association) classification, '6 minutes 'walk distance and measurement of brain natriuretic peptide (NT-proBNP) test was also be performed at baseline and after one year follow-up.

Design

It was an interventional prospective not blinded randomized single centre study. The investigators randomized fifty patients into two groups (1:1 ratio) between May 2018 and December 2021:

Group 1 : 25 patients underwent the implantation of a conventional ventricular pacemaker (Medtronic) with placement of a ventricular lead Medtronic 5076-58 in the right ventricle.

Group 2 : 25 patients underwent the implantation of a leadless pacing system Micra TPS.

All implantation procedures were performed under local anaesthesia. To minimize the impact of the pacing site, the investigators targeted as first position the mid septum of the right ventricle. In the presence of inacceptable electrical measurements, an apical positioning was reached. All pacing positions were reviewed according to the Lieberman criteria.

Patients follow-up Patients were followed for a minimal period of 1 year (at 1 month after implantation, 6 months and 12 months as in routine care). Two-dimensional echocardiography was performed 1 day before implantation and at each visit. A 6 minutes' walk distance was performed at day 10 and at 1 year follow-up. As biological marker of the left ventricular function, brain natriuretic peptide (NT-proBNP) was also measured at baseline and at 1 year follow-up.

Device data collections:

The implant procedure duration as the procedure fluoroscopy times were also recorded. Follow-up of the electrical measurements was performed at the same time than the echocardiographic recording.

All complications (implantation failure, device or lead dislodgements, implantation related infection, death) were also prospectively documented.

Conventional 2D-Echocardiography:

Transthoracic echocardiography was performed using a commercially available ultrasound machine (VividTM E95, GE Vingmed Ultrasound AS; Epiq, Philips Medical Systems). Baseline and follow-up echocardiographic examinations were performed using the same machine. Conventional echocardiographic data were analysed according to the recommendations of the European Association of Cardiovascular Imaging. Standard parasternal long- and short-axis and apical four and two-chamber and long axis view were acquired. Left ventricular end-diastolic volume (LVEDV), end-systolic volume (LVESV) and left ventricular ejection fraction were calculated using Simpson's rule in a four-chamber view.

The ystolic function of the right ventricle was evaluated by tricuspid annular plane systolic excursion (TAPSE) in a standard apical four-chamber view. Finally, valve function and particularly tricuspid function was assessed following the European recommendations.

All echocardiographic values will be obtained from the average of measurements from six continuous normal cardiac beats.

Ethical considerations:

The investigators followed the declaration of Helsinki regarding human experimentation. Moreover, the investigators respected national legislation regarding clinical research and confidentiality of the data obtained in this study. All the participants were informed about the aims and procedures of the study and signed an informed consent form before the inclusion in the study. The local ethical committees reviewed and approved this protocol.

02

Conditions studied

  • Pacing-Induced Cardiomyopathy

Browse trials for

Keywords

  • leadless pacemaker
  • Micra Transcatheter pacemaker
  • ventricular function
  • valve function
03

In context

Cardiomyopathies

1,176 studies on the registry are indexed under Cardiomyopathies; 287 are open to participants now.

This study's enrollment of 51 is close to the median of 51 across 609 interventional studies indexed under Cardiomyopathies.

Browse Cardiomyopathies studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 928 studies on the registry; 261 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with a Class I or II indication for single chamber pacemaker following international guidelines

Exclusion criteria

Exclusion Criteria:

  • patients with previously implanted cardiac devices / mechanical valves that would interfere with the echocardiographic measurements
  • patients with inadequate image quality at baseline that prohibited the assessment of myocardial mechanics using echocardiography
  • patients with a left ventricular ejection fraction (LVEF) ≤40% at baseline
  • patients considered to have a pre-existing condition challenging/precluding the implant of a conventional pacemaker
  • patients who refused or were not able to provide written informed consent.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Active comparator
    Conventional pacing

    24 patients underwent the implantation of a conventional VVI pacing system (Medtronic) with placement of a ventricular pacing lead Medtronic 5076-58 in the right ventricle.

    Device: Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR

  • Experimental
    leadless pacing

    27 patients underwent the implantation of a leadless pacing system Micra TPS

    Device: Micra Transcatheter Pacing System (TPS°

Interventions

  • DeviceMicra Transcatheter Pacing System (TPS°

    Implantation of a leadless pacemaker type Micra TPS. Echocardiographic and clinical follow-up during 12 months

  • DeviceConventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR

    Implantation of a conventional ventricular pacemaker (VVI and VV(R) pacing mode) and right ventricular lead (Medtronic 5076-58)/ Echocardiographic and clinical follow-up during 12 months

06

What researchers measure

Primary outcomes

  1. Assessment and comparison of the mechanical impact of right ventricular pacing using the Micra TPS versus a conventional PM on the left ventricular function.

    The primary endpoints were the change in left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS)

    Time frame: 1 year

Secondary outcomes

  1. Evolution of the right ventricular, tricuspid valve and mitral valve function

    Echocardiographic measurements at baseline and 1-year follow-up

    Time frame: 1 year

  2. Evolution of NT-pro-BNP

    Measurement of NT-pro BNP at baseline and 1-year follow-up

    Time frame: 1 year

  3. Evolution of pacemaker performance

    Measurement of electrical parameters: pacing threshold, impedance and R-wave sensing. Measurement of percentage of ventricular pacing in both groups.

    Time frame: 1 year

07

Study locations

1 site
  • University Hospitals of Leuven
    Leuven, 3000, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06100757
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
Medtronic
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
May 1, 2018
Primary completion
Nov 30, 2021
Completion
Dec 31, 2021
Last update
Oct 31, 2023

Study contacts

Christophe Garweg, MD, PhD
principal investigator · University hospitals of Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion